Immunity to melanin and to tyrosinase in melanoma patients, and in people with vitiligo

BMC Complementary and Alternative Medicine

Volumn 12, Issue , 2012, Pages

  Dordić, Marija ^a   Matić, Ivana Z ^a   Filipović Lješković, Ivana ^a   Džodić, Radan ^a,b   Šašić, Miomir ^a   Erić Nikolić, Aleksandra ^a   Vuletić, Ana ^a   Kolundžija, Branka ^a   Damjanović, Ana ^a   Grozdanić, Nada ^a   Nikolić, Srdan ^a   Pralica, Janko ^a   Dobrosavljević, Danijela ^b,c   Rašković, Sanvila ^b,c   Andrejević, Sladana ^c   Juranić, Zorica ^a  

^a INSTITUTE FOR ONCOLOGY AND RADIOLOGY OF SERBIA   (Serbia)

^b UNIVERSITY OF BELGRADE   (Serbia)

^c CLINICAL CENTER OF SERBIA   (Serbia)

Author keywords

Anti melanin antibodies; Anti tyrosinase antibodies; Melanin; Melanoma; Tyrosinase; Vitiligo

Indexed keywords

CD16 ANTIGEN; CD56 ANTIGEN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN M; MELANIN; MONOPHENOL MONOOXYGENASE;

ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; ENZYME LINKED IMMUNOSORBENT ASSAY; GRANULOCYTE; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; LYMPHOCYTE; MAJOR CLINICAL STUDY; MELANOMA; NATURAL KILLER CELL; PROBABILITY; VITILIGO;

EID: 84866609223     PISSN: None     EISSN: 14726882     Source Type: Journal    
DOI: 10.1186/1472-6882-12-109     Document Type: Article

References (36)

1. Kalialis LV, Drzewiecki KT, Klyver H. Spontaneous regression of metastases from melanoma: review of the literature. Melanoma Res 2009, 19:275-282. 10.1097/CMR.0b013e32832eabd5, 19633580.
2. Schadendorf D, Algarra SM, Bastholt L, Cinat G, Dreno B, Eggermont AM, Espinosa E, Guo J, Hauschild A, Petrella T, Schachter J, Hersey P. Immunotherapy of distant metastatic disease. Ann Oncol 2009, 20(Suppl 6):41-50.
3. Carretero R, Wang E, Rodriguez AI, Reinboth J, Ascierto ML, Engle AM, Liu H, Camacho FM, Marincola FM, Garrido F, Cabrera T. Regression of melanoma metastases after immunotherapy is associated with activation of antigen presentation and interferon-mediated rejection genes. Int J Cancer 2011,
4. Turcotte S, Rosenberg SA. Immunotherapy for metastatic solid cancers. Adv Surg 2011, 45:341-360. 10.1016/j.yasu.2011.04.003, 21954698.
5. Damian DL, Shannon KF, Saw RP, Thompson JF. Topical diphencyprone immunotherapy for cutaneous metastatic melanoma. Australas J Dermatol 2009, 50:266-271. 10.1111/j.1440-0960.2009.00556.x, 19916970.
6. Amaria RN, Lewis KD, Gonzalez R. Therapeutic options in cutaneous melanoma: latest developments. Ther Adv Med Oncol 2011, 3:245-251. 10.1177/1758834011415308, 3169931, 21957431.
7. Yuan J, Adamow M, Ginsberg BA, Rasalan TS, Ritter E, Gallardo HF, Xu Y, Pogoriler E, Terzulli SL, Kuk D, Panageas KS, Ritter G, Sznol M, Halaban R, Jungbluth AA, Allison JP, Old LJ, Wolchok JD, Gnjatic S. Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab. Proc Natl Acad Sci USA 2011, 108:16723-16728. 10.1073/pnas.1110814108, 3189057, 21933959.
8. Vajdic CM, van Leeuwen MT, Webster AC, McCredie MR, Stewart JH, Chapman JR, Amin J, McDonald SP, Grulich AE. Cutaneous melanoma is related to immune suppression in kidney transplant recipients. Cancer Epidemiol Biomarkers Prev 2009, 18:2297-2303. 10.1158/1055-9965.EPI-09-0278, 19622722.
9. Rosenberg SA, Yang JC, Sherry RM, Kammula US, Hughes MS, Phan GQ, Citrin DE, Restifo NP, Robbins PF, Wunderlich JR, Morton KE, Laurencot CM, Steinberg SM, White DE, Dudley ME. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res 2011, 17:4550-4557. 10.1158/1078-0432.CCR-11-0116, 3131487, 21498393.
10. Sondak VK, Flaherty LE. Targeted therapies: Improved outcomes for patients with metastatic melanoma. Nat Rev Clin Oncol 2011, 8:513-515. 10.1038/nrclinonc.2011.119, 21788973.
11. Eggermont AM, Robert C. New drugs in melanoma: it's a whole new world. Eur J Cancer 2011, 47:2150-2157. 10.1016/j.ejca.2011.06.052, 21802280.
12. Van Nuffel AM, Benteyn D, Wilgenhof S, Corthals J, Heirman C, Neyns B, Thielemans K, Bonehill A. Intravenous and intradermal TriMix-dendritic cell response and durable tumor response in a chemorefractory stage IV-M1c melanoma patient. Cancer Immunol Immunother 2011,
13. Nishitani N, Bito T, Ikeda T, Tokura Y, Nishigori C. Complete remission of metastatic malignant melanoma after surgery in association with development of systemic vitiligo. J Dermatol 2010, 37:770-772. 10.1111/j.1346-8138.2010.00877.x, 20649729.
14. Byrne KT, Turk MJ. New perspectives on the role of vitiligo in immune responses to melanoma. Oncotarget 2011, 2:684-694. 3248219, 21911918.
15. Ridolfi L, Petrini M, Fiammenghi L, Granato AM, Ancarani V, Pancisi E, Brolli C, Selva M, Scarpi E, Valmorri L, Nicoletti SV, Guidoboni M, Riccobon A, Ridolfi R. Dendritic cell-based vaccine in advanced melanoma: update of clinical outcome. Melanoma Res 2011, 21:524-529. 10.1097/CMR.0b013e32834b58fa, 21909041.
16. Fiammenghi L, Ancarani V, Rosales T, Knutson JR, Petrini M, Granato AM, Pancisi E, Ridolfi L, Ridolfi R, Riccobon A, Neyroz P. FRET microscopy autologous tumor lysate processing in mature dendritic cell vaccine therapy. J Transl Med 2010, 8:52. 10.1186/1479-5876-8-52, 2894751, 20525246.
17. Nakai N, Hartmann G, Kishimoto S, Katoh N. Dendritic cell vaccination in human melanoma: relationships between clinical effects and vaccine parameters. Pigment Cell Melanoma Res 2010, 23:607-619. 10.1111/j.1755-148X.2010.00736.x, 20579307.
18. Schiltz PM, Dillman RO, Korse CM, Cubellis JM, Lee GJ, De Gast GC. Lack of elevation of serum S100B in patients with metastatic melanoma as a predictor of outcome after induction with an autologous vaccine of proliferating tumor cells and dendritic cells. Cancer Biother Radiopharm 2008, 23:214-221. 10.1089/cbr.2007.0432, 18454690.
19. Juranić ZD, Besu I, Jelić S, Konić-Ristić A, Matković S, Janković L, Gavrilović D, Radojcić B, Minić I. Some patients with NHL possessed immunoreactivity to gliadin and to cow's milk proteins. Int J Hematol 2009, 90:212-216. 10.1007/s12185-009-0383-5, 19609644.
20. Konic-Ristic A, Dodig D, Krstic R, Jelic S, Stankovic I, Ninkovic A, Radic J, Besu I, Bonaci-Nikolic B, Jojic N, Djordjevic M, Popovic D, Juranic Z. Different levels of humoral immunoreactivity to different wheat cultivars gliadin are present in patients with celiac disease and in patients with multiple myeloma. BMC Immunol 2009, 10:32. 10.1186/1471-2172-10-32, 2696423, 19480718.
21. Besu I, Jankovic L, Magdu IU, Konic-Ristic A, Raskovic S, Juranic Z. Humoral immunity to cow's milk proteins and gliadin within the etiology of recurrent aphthous ulcers?. Oral Dis 2009, 15:560-564. 10.1111/j.1601-0825.2009.01595.x, 19563417.
22. Merimsky O, Shoenfeld Y, Fishman P. A focus on anti-tyrosinase antibodies in melanoma and vitiligo. The Decade of Autoimmunity 1999, 261-267. Elsevier Science B.V, Amsterdam.
23. Fishman P, Merimski O, Baharav E, Shoenfeld Y. Autoantibodies to tyrosinase: the bridge between melanoma and vitiligo. Cancer 1997, 79:1461-1464. 10.1002/(SICI)1097-0142(19970415)79:8<1461::AID-CNCR3>3.0.CO;2-E, 9118024.
24. Baharav E, Merimski O, Shoenfeld Y, Zigelman R, Gilbrud B, Yecheskel G, Youinou P, Fishman P. Tyrosinase as an autoantigen in patients with vitiligo. Clin Exp Immunol 1996, 105:84-88. 10.1046/j.1365-2249.1996.d01-727.x, 2200479, 8697641.
25. Revskaya E, Jongco AM, Sellers RS, Howell RC, Koba W, Guimaraes AJ, Nosanchuk JD, Casadevall A, Dadachova E. Radioimmunotherapy of experimental human metastatic melanoma with melanin-binding antibodies and in combination with dacarbazine. Clin Cancer Res 2009, 15:2373-2379. 10.1158/1078-0432.CCR-08-2376, 19293257.
26. Juranic ZD, Stanojevic-Bakic N, Zizak Z, Babovic N, Radovic-Kovacevic V, Stanojkovic T, Dzodic R. Antimelanoma immunity in vitiligo and melanoma patients. Neoplasma 2003, 50:305-309.
27. Holtan SG, Creedon DJ, Thompson MA, Nevala WK, Markovic SN. Expansion of CD16-negative natural killer cells in the peripheral blood of patients with metastatic melanoma. Clin Dev Immunol 2011, 2011:316314. 3049347, 21403861.
28. Cartei G, Sala PG, Sanzari M, Ceschia V, Clocchiatti L, Sibau A, Donà S, Giovannoni M, Vigevani E. Reduced lymphocyte subpopulations in patients with advanced or disseminated melanoma. J Am Acad Dermatol 1993, 28:738-744. 10.1016/0190-9622(93)70103-Z, 8496418.
29. Pérez-Berezo T, Franch A, Castellote C, Castell M, Pérez-Cano FJ. Mechanisms involved in down-regulation of intestinal IgA in rats by high cocoa intake. J Nutr Biochem 2011, 10.1016/j.jnutbio.2011.04.008.
30. Ramiro-Puig E, Pérez-Cano FJ, Ramos-Romero S, Pérez-Berezo T, Castellote C, Permanyer J, Franch A, Izquierdo-Pulido M, Castell M. Intestinal immune system of young rats influenced by cocoa-enriched diet. J Nutr Biochem 2008, 19:555-565. 10.1016/j.jnutbio.2007.07.002, 18061430.
31. Park JS, Mathison BD, Hayek MG, Massimino S, Reinhart GA, Chew BP. Astaxanthin stimulates cell-mediated and humoral immune responses in cats. Vet Immunol Immunopathol 2011, 144:455-461. 10.1016/j.vetimm.2011.08.019, 21930306.
32. Schlaak M, Schmidt P, Bangard C, Kurschat P, Mauch C, Abken H. Regression of metastatic melanoma in a patient by antibody targeting of cancer stem cells. Oncotarget 2012, 3:22-30. 3292889, 22289880.
33. Mueller T, Voigt W. Fermented wheat germ extract - nutritional supplement or anticancer drug?. Nutr J 2011, 10:89. 10.1186/1475-2891-10-89, 3179707, 21892933.
34. Sato K, Takahashi H, Toriyama M. Depigmenting mechanism of NSAIDs on B16F1 melanoma cells. Arch Dermatol Res 2011, 303:171-180. 10.1007/s00403-010-1094-8, 21079976.
35. Sadowska AM, Manuel-y-Keenoy B, Vertongen T, Schippers G, Radomska-Lesniewska D, Heytens E, De Backer WA. Effect of N-acetylcysteine on neutrophil activation markers in healthy volunteers: in vivo and in vitro study. Pharmacol Res 2006, 53:216-225. 10.1016/j.phrs.2005.11.003, 16384711.
36. Ohno M, Abe T. Rapid colorimetric assay for the quantification of leukemia inhibitory factor (LIF) and interleukin-6 (IL-6). J Immunol Methods 1991, 145:199-203. 10.1016/0022-1759(91)90327-C, 1765652.